{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:45:14Z","timestamp":1773834314774,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["15-33-70003"],"award-info":[{"award-number":["15-33-70003"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["16-03-00136"],"award-info":[{"award-number":["16-03-00136"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00922","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T03:29:46Z","timestamp":1513222186000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["The Evaluation of Pharmacodynamics and Pharmacokinetics of Anti-thrombin DNA Aptamer RA-36"],"prefix":"10.3389","volume":"8","author":[{"given":"Elena","family":"Zavyalova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadezhda","family":"Samoylenkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Revishchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Askar","family":"Turashev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya","family":"Gordeychuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Golovin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Kopylov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Pavlova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/355564a0","article-title":"Selection of single stranded DNA molecules that bind and inhibit human thrombin.","volume":"355","author":"Bock","year":"1992","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/bmc.2998","article-title":"Development and validation of a highly sensitive LC-MS\/MS method for quantitation of bivalirudin in human plasma: application to a human pharmacokinetic study.","volume":"27","author":"Chai","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1021\/jm901743x","article-title":"Leech-derived thrombin inhibitors: from structures to mechanisms to clinical applications.","volume":"53","author":"Corral-Rodr\u0131guez","year":"2010","journal-title":"J. Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1517\/13543784.2013.821463","article-title":"Investigational anticoagulants for hematological conditions: a new generation of therapies.","volume":"22","author":"Denas","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B5","year":"2005","journal-title":"Scientific Discussion for the Approval of Angiox."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1574890109666141205132531","article-title":"Specific antidotes in development for reversal of novel anticoagulants: a review.","volume":"9","author":"Fern\u00e1ndez","year":"2014","journal-title":"Recent Pat. Cardiovasc. Drug Discov."},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5811\/westjem.2014.12.22933","article-title":"Anticoagulation drug therapy: a review.","volume":"16","author":"Harter","year":"2015","journal-title":"West. J. Emerg. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1007\/s11095-004-7676-4","article-title":"Pharmacokinetics and biodistribution of novel aptamer compositions.","volume":"21","author":"Healy","year":"2004","journal-title":"Pharm. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics.","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/187152509787047658","article-title":"Nucleotide-derived thrombin inhibitors: a new tool for an old issue.","volume":"7","author":"Lancellotti","year":"2009","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1023\/A:1016295907266","article-title":"A novel oligodeoxynucleotide inhibitor of thrombin. II. Pharmacokinetics in the cynomolgus monkey.","volume":"12","author":"Lee","year":"1995","journal-title":"Pharm. Res."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057341","article-title":"Selection of an aptamer antidote to the anticoagulant drug bivalirudin.","volume":"8","author":"Martin","year":"2013","journal-title":"PLOS ONE"},{"key":"B13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1161\/01.ATV.0000193624.28251.83","article-title":"What does it take to make the perfect clot?","volume":"26","author":"Monroe","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/nat.2015.0581","article-title":"Translation and clinical development of antithrombotic aptamers.","volume":"26","author":"Nimjee","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1517\/14712598.4.10.1641","article-title":"Regulatable aptamers in medicine: focus on antithrombotic strategies.","volume":"4","author":"Potti","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00133","article-title":"A new paradigm shift in antithrombotic therapy.","volume":"4","author":"Pudusseri","year":"2013","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1067\/mcp.2002.124522","article-title":"Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.","volume":"71","author":"Robson","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1023\/A:1011980716659","article-title":"Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats.","volume":"15","author":"Reyderman","year":"1998","journal-title":"Pharm. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00018-006-6219-z","article-title":"Direct thrombin inhibitors \u2013 a survey of recent developments.","volume":"63","author":"Schwienhorst","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1023\/A:1016243923195","article-title":"A novel oligodeoxynucleotide inhibitor of thrombin. I.","volume":"12","author":"Shaw","year":"1995","journal-title":"In vitro"},{"key":"B21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2174\/22102892010010100118","article-title":"Aptamer therapeutics: the 21st century\u2019s magic bullet of nanomedicine.","volume":"1","author":"Shigdar","year":"2010","journal-title":"Open Conf. Proc. J."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-014-0588-8","article-title":"Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.","volume":"18","author":"Treschan","year":"2014","journal-title":"Crit. Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ijcard.2016.03.056","article-title":"Specific antidotes against direct oral anticoagulants: a comprehensive review of clinical trials data.","volume":"214","author":"Tummala","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1134\/S0006297916030068","article-title":"Effect of thrombin inhibitors on positive feedback in the coagulation cascade.","volume":"81","author":"Ustinov","year":"2016","journal-title":"Biochemistry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1161\/ATVBAHA.115.300131","article-title":"Modulation of the coagulation cascade using aptamers.","volume":"35","author":"Woodruff","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.2174\/09298673113206660283","article-title":"Module-activity relationship of G-quadruplex based DNA aptamers for human thrombin.","volume":"20","author":"Zavyalova","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.2174\/1381612822666161004163409","article-title":"Development of antithrombotic aptamers: from recognizing elements to drugs.","volume":"22","author":"Zavyalova","year":"","journal-title":"Curr. Pharm. Des."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.2174\/092986711796504727","article-title":"Novel modular DNA aptamer for human thrombin with high anticoagulant activity.","volume":"18","author":"Zavyalova","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.2174\/092986712803530575","article-title":"DNA aptamers for human thrombin with high anticoagulant activity demonstrate target- and species-specificity.","volume":"19","author":"Zavyalova","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107113","article-title":"Evaluation of antithrombotic activity of thrombin DNA aptamers by a murine thrombosis model.","volume":"9","author":"Zavyalova","year":"2014","journal-title":"PLOS ONE"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.2174\/0929867323666160517120126","article-title":"G-quadruplex aptamers to human thrombin versus other direct thrombin inhibitors: the focus on mechanism of action and drug efficiency as anticoagulants.","volume":"23","author":"Zavyalova","year":"","journal-title":"Curr. Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/aps.2012.37","article-title":"Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.","volume":"33","author":"Zhang","year":"2012","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00922\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T12:00:29Z","timestamp":1526385629000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00922\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":32,"alternative-id":["10.3389\/fphar.2017.00922"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00922","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]},"article-number":"922"}}